Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab.

ABSTRACT:

Objective

The aim of this study was to evaluate minimal disease activity (MDA) assessments in patients with PsA during routine clinical care.

Methods

We used data from a multicentre observational study of patients with active PsA who initiated treatment with adalimumab during routine clinical practice and continued treatment for at least 6 months to evaluate achievement of MDA, individual MDA criteria (modified to conform to study assessments) and ACR responses during 24 months of therapy. Pearson correlation coefficients were used to evaluate the association between MDA and individual criteria at month 6; regression models were used to determine the influence of baseline MDA criteria on achievement of MDA at month 6.

Results

A total of 1684 patients were included in

SUBMITTER: Behrens F 

PROVIDER: S-EPMC6199539 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature